Clinical Trial

ShOckwave ballooN or Atherectomy With Rotablation in Calcified Coronary Artery Lesions, the SONAR Trial

Study acronym: SONAR
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2024 (before its estimated January 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Percutaneous coronary interventions (PCI) is intended to relieve myocardial ischemia by improving blood flow in the epicardial coronary arteries. However, the efficacy of PCI may be compromised by incidental microvascular obstruction and peri-procedural myocardial infarction (PPMI), which occurs in about 10-15% of cases and is associated with increased rates of major adverse cardiovascular events (MACE). The mechanism of PPMI is thought to be related to side branch occlusion, coronary artery dissection and acute microvascular damage caused by embolization of plaque debris during the PCI and is more frequently seen in calcified coronary artery disease. Calcium modification by rotational atherectomy (RA) results in peri-procedural myocardial infarction in 24% of cases and myocardial injury in 70% of cases. The Shockwave coronary intravascular lithotripsy (IVL) balloon catheter emits sonic pressure waves in a circumferential field causing the selective fracture of calcium, altering vessel compliance and permitting further expansion of the vessel wall. This provides a potentially safer alternative to other calcium-modifying devices since there is a low risk of dissection and perforation. It is also proposed that this IVL device reduces the risk of atheromatous embolization, which would reduce the risk of PPMI and microvascular dysfunction. The SONAR Trial is a pilot study measuring peri-procedural myocardial injury, PPMI and microvascular dysfunction in patients (with calcified coronary artery lesions not responding to usual balloon dilatation) randomized to RA or Shockwave IVL. The primary outcome is peri-procedural myocardial infarction. Secondary outcomes include peri-procedural myocardial injury, acute microvascular dysfunction, procedural success, and procedural costs.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05208749
Lead Sponsor Universitaire Ziekenhuizen KU Leuven
Collaborators: Ziekenhuis Oost-Limburg, University Hospital, Ghent, Universitair Ziekenhuis Brussel, Ziekenhuis Netwerk Antwerpen (ZNA), Imelda Hospital, Bonheiden, AZ Sint-Lucas Brugge, Centre Hospitalier Universitaire Saint Pierre, Hôpital Jolimont
Conditions Calcified Atheroma, Coronary Artery Disease
Enrollment 170 participants
Start Date 2022-02-04
Primary Completion 2025-01-01 (estimated)
Study Completion 2025-01-01 (estimated)
Updated on ClinicalTrials.gov 2024-07-03